
246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid
The Readout Loud
00:00
Is It Hard to Find Interesting Assets?
Is it because interesting assets that you do find either their highly valued or maybe overpriced? Or is it just difficult to find interesting assets like that the science or the companies that are out there are starting up, that they're wanting in some way, and you guys are just kind of passing on them? I think there's three categories. There's companies that have very good assets or very good science and the markets have very well valued them. And then if you want to play in that space, you have to pay significant premiums. We're trying to take a financially disciplined approach about how we approach this kind of what I would characterize as very well analyzed, well valued companies.
Transcript
Play full episode